Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| GHRP-6 | KPV | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection. | Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation. |
| Timing | On empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical. | Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous. |
| Cycle Duration | 8-16 week cycles. | 4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates GH release through activation of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) on pituitary somatotrophs. It acts via dual sites — pituitary and hypothalamic — possibly involving regulatory factors beyond GHRH and somatostatin. GHRP-6 also stimulates ghrelin-mediated appetite signaling, increases cortisol and prolactin release, and has demonstrated cytoprotective properties including cardioprotection.
Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
On empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical.
8-16 week cycles.
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that inhibits NF-kB signaling through a non-melanocortin receptor-mediated mechanism. It is transported intracellularly via the PepT1 transporter, where it stabilizes IkB-alpha and suppresses nuclear translocation of p65RelA by competing with importin-beta at the armadillo domain 7 and 8 binding site. It also reduces MAPK inflammatory signaling and IL-8 secretion in intestinal epithelial cells.
Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation.
Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous.
4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision.
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →